Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Al-Sanea, Mohammad M. | - |
dc.contributor.author | Elkamhawy, Ahmed | - |
dc.contributor.author | Paik, Sora | - |
dc.contributor.author | Bua, Silvia | - |
dc.contributor.author | Lee, So Ha | - |
dc.contributor.author | Abdelgawad, Mohamed A. | - |
dc.contributor.author | Roh, Eun Joo | - |
dc.contributor.author | Eldehna, Wagdy M. | - |
dc.contributor.author | Supuran, Claudiu T. | - |
dc.date.accessioned | 2024-01-19T21:02:34Z | - |
dc.date.available | 2024-01-19T21:02:34Z | - |
dc.date.created | 2021-09-04 | - |
dc.date.issued | 2019-01-01 | - |
dc.identifier.issn | 1475-6366 | - |
dc.identifier.uri | https://pubs.kist.re.kr/handle/201004/120488 | - |
dc.description.abstract | Carbonic anhydrases (CAs, EC 4.2.1.1) are crucial metalloenzymes that are involved in diverse bioprocesses. We report the synthesis and biological evaluation of novel series of benzenesulfonamides incorporating un/substituted ethyl quinoline-3-carboxylate moieties. The newly synthesised compounds were in vitro evaluated as inhibitors of the cytosolic human (h) isoforms hCA I and II. Both isoforms hCA I and II were inhibited by the quinolines reported here in variable degrees: hCA I was inhibited with K(I)s in the range of 0.966-9.091 mu M, whereas hCA II in the range of 0.083-3.594 mu M. The primary 7-chloro-6-flouro substituted sulphfonamide derivative 6e (K-I = 0.083 mu M) proved to be the most active quinoline in inhibiting hCA II, whereas, its secondary sulfonamide analog failed to inhibit the hCA II up to 10 mu M, confirming the crucial role of the primary sulphfonamide group, as a zinc-binding group for CA inhibitory activity. | - |
dc.language | English | - |
dc.publisher | TAYLOR & FRANCIS LTD | - |
dc.subject | DRUG DISCOVERY | - |
dc.subject | THERAPEUTIC APPLICATIONS | - |
dc.subject | SELECTIVE INHIBITORS | - |
dc.subject | ISOZYME-II | - |
dc.subject | SULFONAMIDES | - |
dc.subject | QUINOLINE | - |
dc.subject | DERIVATIVES | - |
dc.subject | POTENT | - |
dc.subject | PATENT | - |
dc.subject | VII | - |
dc.title | Synthesis and biological evaluation of novel 3-(quinolin-4-ylamino)benzenesulfonamidesAQ3 as carbonic anhydrase isoforms I and II inhibitors | - |
dc.type | Article | - |
dc.identifier.doi | 10.1080/14756366.2019.1652282 | - |
dc.description.journalClass | 1 | - |
dc.identifier.bibliographicCitation | JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, v.34, no.1, pp.1457 - 1464 | - |
dc.citation.title | JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY | - |
dc.citation.volume | 34 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 1457 | - |
dc.citation.endPage | 1464 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.identifier.wosid | 000480723600001 | - |
dc.identifier.scopusid | 2-s2.0-85071025700 | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | DRUG DISCOVERY | - |
dc.subject.keywordPlus | THERAPEUTIC APPLICATIONS | - |
dc.subject.keywordPlus | SELECTIVE INHIBITORS | - |
dc.subject.keywordPlus | ISOZYME-II | - |
dc.subject.keywordPlus | SULFONAMIDES | - |
dc.subject.keywordPlus | QUINOLINE | - |
dc.subject.keywordPlus | DERIVATIVES | - |
dc.subject.keywordPlus | POTENT | - |
dc.subject.keywordPlus | PATENT | - |
dc.subject.keywordPlus | VII | - |
dc.subject.keywordAuthor | Benzenesulfonamides | - |
dc.subject.keywordAuthor | carbonic anhydrase | - |
dc.subject.keywordAuthor | quinolines | - |
dc.subject.keywordAuthor | synthesis | - |
dc.subject.keywordAuthor | cytosolic isoforms hCA I and II | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.